Biotech stocks for your portfolio: Galena Biopharma, Inc.

New Post Public Reply Private Reply Replies (0) Message Board
fitzkarz
Biotech stocks for your portfolio: Galena Biopharma, Inc. (GALE), Celldex Therapeutics, Inc (CLDX)
The American Red Cross

Galena Biopharma, Inc. (GALE) ended last trading session with a change of -3.97 percent. It trades at an average volume of 2.34M shares versus 2.37M shares recorded at the end of last trading session. The share price of $1.45 is at a distance of 145.76 percent from its 52-week low and down -39.33 percent versus its peak. The company has a market cap of $240.57M and currently has 165.91M shares outstanding. The share price is currently 28.72 percent versus its SMA20, 56.86 percent versus its SMA50, and 4.23 percent versus its SMA200. The stock has a weekly performance of 6.62 percent and is -1.36 percent year-to-date as of the recent close.

Galena Biopharma, Inc. (GALE) on March 29, 2016 announced that the 70th qualifying disease free survival (DFS) event has been achieved in the NeuVax™ (nelipepimut-S) Phase 3, PRESENT (Prevention of Recurrence in Early-Stage, Node Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) clinical trial. NeuVax is a peptide immunotherapy vaccine currently being evaluated for the prevention of cancer recurrence and is Galena’s lead development agent in multiple ongoing and planned clinical trials.

Based on clinical and radiological data, seventy qualifying DFS events have been confirmed by the trial’s independent Endpoint Adjudication Committee (EAC), comprised of two oncologists and one radiologist with expertise in the conduct of clinical trials in breast cancer. In the ensuing months, Galena will compile and submit the clinical data to the trial’s Independent Data Monitoring Committee (IDMC) to perform the Interim Analysis. The Interim Analysis is a pre-specified futility and overall safety analysis to evaluate the likelihood of the study to achieve its primary objectives. Upon completion of this prospective analysis, the IDMC will provide a recommendation to the Company regarding further continuation of the trial.

PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) is an international, Phase 3 study to evaluate NeuVax plus granulocyte macrophage-colony stimulating factor (GM-CSF) versus placebo plus GM-CSF to prevent cancer recurrence. The trial is being run under a Special Protocol Assessment (SPA) granted by the U.S. Food and Drug Administration (FDA). PRESENT is targeting patients who are node positive, HER2 IHC 1+/2+, and HLA A2+ and/or A3+. The study is double blind, randomized 1:1, and is stratified by stage, type of surgery, hormone receptor status, and menopausal status. Galena enrolled a total of 758 patients who constitute the Intention to Treat (ITT) population, and the primary endpoint for the trial is disease free survival (DFS) upon reaching 141 events with 3 years minimum follow-up.

Celldex Therapeutics, Inc. (CLDX) recently recorded -3.68 percent change and currently at $4.71 is 59.12 percent away from its 52-week low and down -84.45 percent versus its peak. It has a past 5-day performance of 24.6 percent and trades at an average volume of 4.18M shares. The stock has a 1-month performance of 27.99 percent and is -69.96 percent year-to-date as of the recent close. There were about 98.65M shares outstanding which made its market cap $464.64M. The share price is currently 27.59 percent versus its SMA20, -19.56 percent versus its SMA50, and -66.25 percent versus its SMA200.

Celldex Therapeutics, Inc. (CLDX) on March 7, 2016 announced that the independent Data Safety and Monitoring Board (DSMB) has determined, based on a preplanned interim analysis, that continuation of the Phase 3 ACT IV study of RINTEGA® (rindopepimut) in patients with newly diagnosed EGFRvIII-positive glioblastoma will not reach statistical significance for overall survival in patients with minimal residual disease, the primary endpoint of the study, as both the RINTEGA arm and the control arm are performing on par with each other. In the ACT IV study, RINTEGA has performed consistently with prior Phase 2 studies but the control arm has significantly outperformed expectations (Hazard ratio = 0.99; median OS: RINTEGA 20.4 months vs. control 21.1 months). Based on this recommendation, Celldex is discontinuing the study and does not anticipate incurring substantial additional costs related to RINTEGA at this time. All patients on the RINTEGA arm of the ACT IV study, prior Phase 2 studies and existing compassionate use recipients will be offered ongoing access to RINTEGA on a compassionate use basis. Celldex first received the data after market close on Friday, March 4th and is in the process of reviewing the results.

Celldex currently has seven company-led clinical trials across five product candidates ongoing. The Company expects to report data from a number of these studies over the next three to 18 months, including a registration study in triple negative breast cancer and a number of Phase 1 and 2 cancer immunotherapy combination trials.

I'm in it to win it!

NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.

I was born with it, I'm truly blessed!


Alway's searching for winners'
937206596_images.jpg
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sogroya Approval Broadens Novo's Pediatric Growth Franchise

Updated Category News Views 53

Seven fewer injections every week is the real headline behind Novo Nordisk's latest FDA clearance, not some flashy efficacy leap. On November 20, 2026, the company said Sogroya, its once-weekly long-acting growth hormone, won approval for children aged 2.5 and older with growth failure associated with Turner syndrome. That matters because treatment can stretch over years,...

Continue Reading
Rosenblatt Book Puts Vegas Casino Blind Spots on Display

Updated Category News Views 143

A locked casino floor is supposed to make secrets expensive. That is why the pitch behind ROSENBLATT lands with a little more weight than the usual Vegas chest-thumping: the coming memoir says Darryl Rosenblatt became a million-dollar gambler while using none of his own money, and that casino operators did not grasp the full shape of what had happened for years. Take a...

Continue Reading
Foresight Solar Insurance Trial Beats Fixed PPA Route

Updated Category News Views 72

Six solar sites and one settled insurance contract have produced a result worth studying, not celebrating with confetti. Foresight and Paratus say their completed renewable-price insurance policy generated a £14.49/MWh net uplift, after premium, against the revenue those assets would have earned under a fixed-price power purchase agreement. In a UK renewables market...

Continue Reading
BioVersys AlpE Data Offers a Measured TB Treatment Signal

Updated Category News Views 119

Tuberculosis drug development rarely hands anybody a clean victory lap, and BioVersys' latest readout is no exception. The completed 14-day Phase 2a ENABLE study gives alpibectir plus ethionamide, known as AlpE, a credible early clinical signal in newly diagnosed drug-sensitive pulmonary TB. That matters. It does not, however, settle the far larger question of whether...

Continue Reading
AI Shopping Answers Are Becoming Retail's New Shelf

Updated Category News Views 67

Retail’s front door is quietly being moved by a machine, and plenty of big chains appear to be staring at the old entrance. Bain’s latest work lands on an uncomfortable point: owning market share does not guarantee a retailer gets named when an AI assistant answers a shopper’s question. That ought to rattle management teams more than the usual holiday-season...

Continue Reading
Tigo's Guidance Gap Draws Lawsuit and Investor Scrutiny

Updated Category News Views 84

A Revenue Promise Hit the Wall Solar investing can turn ugly in a hurry when a supposedly near-term catalyst gets shoved down the calendar. That is the central bruise behind the securities class action involving Tigo Energy, not some arcane accounting footnote that only lawyers can love. The complaint alleges Tigo overstated the revenue contribution it expected from its...

Continue Reading
KONST Pitches Asia GPU Uptime as AI Demand Gets Real

Updated Category News Views 115

GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...

Continue Reading
Hoymiles Brings Plug-In Solar Flexibility to RE+ 2026

Updated Category News Views 70

A 1.8-kilogram box may not sound like much, but it captures where household solar is trying to go: smaller, less intimidating, and far easier to put to work. At RE+ 2026 in Las Vegas, Hoymiles laid out a residential lineup spanning plug-in solar, battery storage and conventional rooftop microinverters. This was not one flashy gadget looking for applause. It was a fairly...

Continue Reading
AlphaPoint's Approval Device Targets AI Attack Risk

Updated Category News Views 45

A Separate Screen May Be Worth More Than Another Patch AlphaPoint is taking a fairly old security instinct and aiming it at a very current headache: if the laptop is lying to the employee, do not let the laptop have the final say. Its newly introduced Approval Device is dedicated hardware with its own display, built to let authorized staff inspect and approve sensitive...

Continue Reading
Saturn and Tileward Put GPU Memory Back to Work Now

Updated Category News Views 49

GPU memory is the tollbooth nobody notices until the whole AI highway backs up. Saturn Cloud’s new partnership with Tileward goes straight at that constraint: use compressed open-model weights, free memory on hardware already installed, and turn that reclaimed capacity into more tokens that an operator can actually sell. It is not glamorous. It may be one of the more...

Continue Reading

Top 5 Most Recently Viewed Articles

Global Circuit Breaker Market Set for Growth Beyond USD 9 Billion

Updated Category News Views 207

Growing Demand for Circuit Breakers in Diverse Industries The circuit breaker market is gearing up for significant growth, projected to reach a remarkable valuation of USD 9.4 billion by 2031. This exciting expansion is largely attributed to the rising demand for electricity and the escalating need for efficient and reliable energy distribution systems. A compound annual...

Continue Reading
Investigation of MoonLake Immunotherapeutics by Law Firm

Updated Category News Views 145

Faruqi & Faruqi's Investigation on Behalf of Investors Faruqi & Faruqi, LLP is actively investigating potential claims for investors of MoonLake Immunotherapeutics (NASDAQ: MLTX). This initiative is aimed at supporting those who have experienced financial losses and educating them about their legal options. Investors affected are encouraged to reach out to the firm's...

Continue Reading
Golden Ocean Group Limited Announces Q2 2024 Results

Updated Category News Views 92

Golden Ocean Group Limited Reports Q2 2024 Financial Results Hamilton, Bermuda – Golden Ocean Group Limited (NASDAQ/OSE: GOGL), recognized as the largest publicly traded owner of large dry bulk vessels, has released its unaudited financial results for the quarter ending June 30, 2024. Financial Highlights In the second quarter of 2024, Golden Ocean achieved a net income...

Continue Reading
Georgia Dental Association Boosts Access to Teledentistry

Updated Category News Views 215

Expanding Access to Oral Health Care in Georgia Governor Signs Milestone Teledentistry Bill into Law Recently, a significant milestone for dental care was achieved with the signing of House Bill 567, aimed at enhancing access to oral health care through teledentistry. This new legislation, advanced by the Georgia Dental Association, is designed to remove barriers that...

Continue Reading
Anticipated Growth in Economic Indicators for Upcoming GDP

Updated Category News Views 132

Anticipated Growth in Economic Indicators for Upcoming GDP The second-quarter GDP report is set to reveal noteworthy developments in the U.S. economy, signaling a moderate recovery in output. Recent estimates, compiled from various nowcasts, suggest an anticipated growth of 1.7% in GDP for this period. Current Economic Outlook This projection remains steady from earlier...

Continue Reading